

October 7, 2021



CV Sciences, Inc. Applauds the California Legislature for Passage of AB 45

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, applauds the California Legislature of its passage of [AB 45](#), which yesterday was signed into law by Governor Gavin Newson. This new law will explicitly permit the retail sale of products containing hemp-derived extracts and cannabinoids, such as CBD.

"As a California-based company, we are very pleased with the enactment of AB 45, which we believe will lead to significant retail expansion of CV Sciences' PlusCBD™ products in our home state, while also serving as a model for responsible CBD legalization for other states," said Joseph Dowling, Chief Executive Officer of CV Sciences. "AB 45 will provide Californians with access to the health and wellness benefits of our safe and effective hemp-derived CBD. We look forward to working with our retail partners to rapidly expand our distribution footprint in California."

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing, and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company's PlusCBD™ products are sold at more than 7,300 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company's products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those

sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

Media Contact

ICR

Cory Ziskind

646-277-1232

cory.ziskind@icrinc.com

Investor Contact

ICR

Reed Anderson

646-277-1260

CVSciences@icrinc.com

CV SCIENCES™

Source: CV Sciences, Inc.